TORONTO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that Revive has entered into an exclusive license agreement (the “Agreement”) with Puerto Rico Science Technology and Research Trust (“PRSTRT”), representing Universidad Central del Caribe (“UCC”) and St. Jude Children’s Research Hospital (“St. Jude”), for the intellectual property (International Patent Application No. PCT/US2020/017053/) titled, Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization. Researchers at St. Jude and UCC have characterized medicinal mushroom Ganoderma lucidum compounds with anti-cancer activity, specifically signi?cant activity against breast cancer, thus having the potential to treat the most aggressive types of breast cancers such as triple negative breast cancer and in?ammatory breast cancer.

See the rest here:
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer